Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2012
At a glance
- Drugs Dasatinib (Primary) ; Temozolomide
- Indications Glioma
- Focus Adverse reactions
- 22 Jan 2009 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.
- 22 Jan 2009 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 22 Jan 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.